Clinical Trial

Vancomycin in Primary Sclerosing Cholangitis in Italy

Study acronym: VanC-IT
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Primary sclerosing cholangitis (PSC) is chronic fibroinflammatory disease of the liver. There is still no medical therapy proven to halt the progression of PSC or prevent its serious complications. This is a Phase 2 randomized, double bind, placebo-controlled, monocentric study evaluating the safety and efficacy of two doses of oral vancomycin (i.e. 750 mg and 1500 mg/day) in subject between 15 - 70 years old with PSC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-16; most recent amendment 2025-07-24.
Trial Details
NCT Number NCT05876182
Lead Sponsor University of Milano Bicocca
Collaborators: Genetic s.p.a.
Conditions Primary Sclerosing Cholangitis, Liver and Intrahepatic Bile Duct Disorder, IBD
Enrollment 84 participants
Start Date 2023-06-15
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-07-25